Compare Adaptive Biotechnologies Corp (ADPT) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Adaptive Biotechnologies Corp trades at $20.23 (market cap $3.33B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $252.31 (market cap $47.86B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 14.4× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | TTWO | |
|---|---|---|
Market Cap | $3.33B | $47.86B |
Sector | Health | Media |
52-Week High | $22.37 | $262.29 |
52-Week Low | $10.24 | $189.69 |
Enterprise Value | $3.19B | $48.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Take-Two Interactive (TTWO) trades at $257.79, up 1.12% with strong bullish momentum driven by Grand Theft Auto VI pre-orders and recent earnings beats. The stock shows technical strength with bullish moving averages, though RSI indicates overbought conditions. Despite negative net income margins, revenue growth to $5.63B in 2025 and analyst consensus of $302.50 price target reflect optimism around the GTA VI launch in November 2026.
Outlook remains positive with GTA VI as a major catalyst, but risks include high debt levels and profitability challenges. Institutional sentiment is strongly bullish with 79% buy ratings, yet investors should monitor execution risks and competitive pressures in the gaming sector. The stock's valuation metrics like P/S of 7.14 suggest growth expectations are priced in.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
